You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2025

Claims for Patent: 11,723,858

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,723,858

Title:	Topical antiviral compositions, delivery systems, and methods of using the same
Abstract:	The present invention relates generally to topical antiviral compositions, delivery systems, and methods of using the same.
Inventor(s):	Kimberly McHale, Ryan Doxey, Nathan Stasko
Assignee:	Lnhc Inc
Application Number:	US17/329,587
Patent Claims:	1. A delivery system comprising a composition, the composition comprising a nitric oxide (NO)-releasing active pharmaceutical ingredient, wherein the NO-releasing active pharmaceutical ingredient is a diazeniumdiolated co-condensed silica particle and is present in the composition in an amount of 0.01% to 30% by weight of the composition, wherein the composition has a Cmax of greater than 160 pmol of NO/mg, as measured by in vitro release testing, and wherein the composition has a pH of about 5 to about 8. 2. The delivery system of claim 1, wherein the composition stores and/or releases nitric oxide in an amount of about 0.05% to about 10% by weight of the composition. 3. The delivery system of claim 1, wherein the delivery system is configured for delivery to a body cavity of a subject. 4. The delivery system of claim 1, wherein the delivery system is configured to contact the composition to a mucous membrane of the subject. 5. The delivery system of claim 1, wherein the delivery system is configured to contact the composition to a nostril, mouth, tongue, and/or pharynx of the subject. 6. The delivery system of claim 1, wherein the composition further comprises water. 7. The delivery system of claim 1, wherein the delivery system administers nitric oxide in an amount sufficient to induce apoptosis in virally infected cells. 8. The delivery system of claim 1, wherein the delivery system administers nitric oxide in an amount sufficient to reduce or eliminate viral replication with less than about 50% host cell cytotoxicity. 9. The delivery system of claim 1, wherein the diazeniumdiolated co-condensed silica particle comprises a co-condensed silica network comprising diazeniumdiolated aminoethylaminopropyl trimethoxy silane (AEAP3) and tetra methyl orthosilicate (TMOS). 10. The delivery system of claim 1, wherein the diazeniumdiolated co-condensed silica particle comprises a co-condensed silica network comprising diazeniumdiolated methylaminopropyl trimethoxysilane (MAP3) and tetra methyl orthosilicate (TMOS). 11. The delivery system of claim 1, wherein the diazeniumdiolated co-condensed silica particle comprises a co-condensed silica network comprising diazeniumdiolated methylaminopropyl trimethoxysilane (MAP3) and tetraethyl orthosilicate (TEOS). 12. A method of administering nitric oxide to a subject to treat and/or prevent a viral infection in a subject, the method comprising: administering a composition comprising a nitric oxide (NO)-releasing active pharmaceutical ingredient, wherein the NO-releasing active pharmaceutical ingredient is a diazeniumdiolated co-condensed silica particle and is present in the composition in an amount of 0.01% to 30% by weight of the composition, wherein the composition has a Cmax of greater than 160 pmol of NO/mg, as measured by in vitro release testing, and wherein the composition has a pH of about 5 to about 8. 13. The method of claim 12, wherein the composition stores and/or releases nitric oxide in an amount of about 0.05% to about 10% by weight of the composition. 14. The method of claim 12, wherein the administering comprises administering the composition to a body cavity of a subject. 15. The method of claim 12, wherein the administering comprises administering the composition to a mucous membrane of the subject. 16. The method of claim 12, wherein the administering comprises administering the composition to a nostril, mouth, tongue, and/or pharynx of the subject. 17. The method of claim 12, wherein the administering comprises administering nitric oxide in an amount sufficient to induce apoptosis in virally infected cells in the subject. 18. The method of claim 12, wherein the administering comprises administering nitric oxide in an amount sufficient to reduce or eliminate viral replication with less than about 50% host cell cytotoxicity. 19. The method of claim 12, wherein the composition further comprises water. 20. The method of claim 12, wherein the diazeniumdiolated co-condensed silica particle comprises a co-condensed silica network comprising diazeniumdiolated methylaminopropyl trimethoxysilane (MAP3) and tetra methyl orthosilicate (TMOS).

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.